Early Gestational Diabetes Mellitus
- Conditions
- Gestational Diabetes
- Interventions
- Other: late management strategyOther: early management strategy
- Registration Number
- NCT04451915
- Lead Sponsor
- University Hospital, Lille
- Brief Summary
In 2010, the International Association of the Diabetes and Pregnancy Study Groups (IADPSG) panel published consensus-based recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Cognizant that milder degrees of hyperglycemia would also be detected by early pregnancy testing, the IADPSG recommended that fasting plasma glucose (FPG) in the range of 5.1-6.9 mmol/l should be considered diagnostic of early Gestational Diabetes Mellitus (GDM) even if the level of proof for this recommendation is very low regarding to prognosis. This threshold was extrapolated from the FPG value used between 24 and 28 weeks.
In France, a FPG is proposed at the first prenatal visit for women with risk factors of GDM. Early GDM is diagnosed if FPG is ≥ 5.1 mmol/l, leading to an intensive metabolic management. Data have shown that GDM prevalence increased rapidly from 5.9% in 2009 to 9.3% in 2014. 26.9% of women with hyperglycemia during their pregnancy but without known diabetes are treated before 22 weeks' gestation (WG). More recent data from Italy and China, where IADPSG diagnosis criteria were applied, have strongly challenged this recommendation, and showed that early FPG ≥ 5.1mmo/L is poorly predictive of later GDM. No prior studies have demonstrated benefits to early screening and management. In 2016, the IADPSG members have suggested that the use of the FPG threshold ≥5.1 mmol/l for the identification of GDM in early pregnancy is not justified by current evidence
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- Female
- Target Recruitment
- 2010
- Pregnant woman
- Singleton pregnancy
- Early GDM defined by a fasting plasma glucose between 5.1 mmol/l and 6.1 mmol/ with at least one risk factor (age ≥35 years and/or BMI ≥ 25 kg/m2 and/or familial history of diabetes and/or personal history of GDM and/or personal history of macrosomia).
- First prenatal visit prior 20 weeks of gestation at the time of randomization.
- Signed informed consent
Diabetic follow-up started at time of inclusion
- Pre-existing diabetes in pregnancy
- Renal impairment
- Hepatic insufficiency
- History of bariatric surgery
- Long time corticosteroids treatment
- Insufficient understanding
- Language difficulties
- Lack of social Insurance
- Person in emergency situation
- Person under the protection of justice (tutelage/ curatorship)
- Persons deprived of their liberty
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Late management GDM group late management strategy early management of GDM defined as intensive metabolic treatment (diet, physical activity self-blood glucose monitoring according and/or insulin therapy according to the French guidelines). This intensive treatment will begin after the randomization until delivery. Early management GDM group early management strategy defined as no intervention until GDM screening at 24-28 weeks' gestation. If there is a diagnosis of GDM at 24-28 according to the IADPSG criteria), intensive metabolic treatment until delivery
- Primary Outcome Measures
Name Time Method The occurrence of materno-fetal complications at delivery Composite endpoint defined by Large for Gestational Age (LGA) (defined by birth weight ≥90th percentile, adjusted for gestational age, sex, maternal BMI, parity, ethnicity) and/or neonatal hypoglycemia and/or shoulder dystocia and/or birth traumatisms
- Secondary Outcome Measures
Name Time Method Need for insulin during pregnancy at each 10 days until delivery After at least 10 days of dietary and lifestyles measures, if the target are not achieved, women will receive insulin therapy. fastin glucose target \<5.1 mmol/ and/or a 2 hour post prandial capillary glucose \< 6.6 mmol/l
at each 10 days a contact with the diabetologist or the nurses for the transmission of the capillary glycaemia either by phone or by the platform 'myDiabby"Metabolic data: HbA1c at inclusion (because <20 weeks') and an average at 24 28 weeks of gestation Change of value of HbA1c
Oral Glucose Tolerance Test (OGTT) an average at 24 28 weeks of gestation Percent of GDM women in the late GDM management group according to the IADPSG criteria. an average at 24 28 weeks of gestation IADPSG criteria(fasting glucose more or equal to 5.1 mmol/l and/or 1h more or equal to 10.0 mmol/l and /or 2h more or equal to 8.5 mmol/l
Number of complications in each subgroup of the late GDM management group at delivery Maternal and neonatal complication
Correlation between composite endpoint (defined in the outcome 1) and the 5 risk factors of GDM at delivery Correlation between composite endpoint (defined in the outcome 1) and the 5 risk factors of GDM (age more or equal to 35 years, BMI more or equal to 25 kg/m2, familial history of diabetes, personal history of GDM, personal history of macrosomia)
Metabolic data: Fasting plasma glucose at inclusion (because <20 weeks') and an average at 24 28 weeks of gestation Change of value of fasting plasma glucose
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (10)
Hop Claude Huriez Chu Lille
🇫🇷Lille, France
Hopital Saint Vincent - Saint Antoine - Lille
🇫🇷Lille, France
Chu Nimes Caremeau - Nimes 9
🇫🇷Nîmes, France
Ch Rene Dubos - Pontoise
🇫🇷Pontoise, France
Chu Site Sud (Saint Pierre) - St Pierre
🇫🇷Saint-Pierre, France
Hopital de Rangueil Chu Toulouse
🇫🇷Toulouse, France
CH ARRAS
🇫🇷Arras, France
Hopital Estaing - Chu63 - Clermont Ferrand
🇫🇷Clermont-Ferrand, France
Csapa / Hus / Hopital Civil - Strasbourg
🇫🇷Strasbourg, France
Hopital Haut-Leveque - Chu - Pessac
🇫🇷Pessac, France